The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm’s lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy’s Laboratories Ltd.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
Merck & Co. Inc. Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019 after scrapping a policy requiring the drugmaker’s CEOs to retire at the age of 65.
The U.S. Justice Department announced charges against 601 people including doctors and nurses for taking part in healthcare fraud and opioid-related crimes that resulted in more than $2 billion in losses.
A new study finds that one-third of adults in the United States are potentially at risk of depression due to their medications.
South Carolina sued Purdue Pharma, accusing the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic.
Missouri became the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers.
Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.
The U.S. Food and Drug Administration approved Egalet Corp.’s Arymo ER and will allow the company to claim the long-acting opioid painkiller deters abuse by those seeking to dissolve and inject it.
Regular use of pain relievers over many years may increase the risk of hearing loss, a recent study suggests.